LDL-cholesterol lowering agents (statins and PCSK9 inhibitors) and the risk of intracerebral hemorrhage: A network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39755190/
LDL-Cholesterol lowering agents (statins and PCSK-9 inhibitors) was not associated with a significant increased risk of ICH. Our network meta-analysis provides strong evidence for the safety of statins and PCSK-9...
Statins and PCSK-9 inhibitors were not associated with a significant increased risk of intracerebral hemorrhage. Network meta-analysis confirms their safety, though further studies are needed for validation.
Share
Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39176329/
Dyslipidemia refers to the change in the normal levels of one or more lipid components in the bloodstream, which include triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and...
Dyslipidemia, a key cardiovascular risk, is managed through lifestyle changes and lipid-lowering drugs like statins, fibrates, PCSK9 inhibitors, and bempedoic acid. Further trials are needed to assess efficacy and safety.
Share
Dyslipidemia Treatment and Cerebrovascular Disease: Evidence Regarding the Mechanism of Stroke - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38826180/
Dyslipidemia stands as a significant risk factor for stroke, on par with the impact of hypertension, diabetes, and smoking. While the role of dyslipidemia is firmly established in the context...
Dyslipidemia significantly influences stroke risk, with varying impacts across stroke subtypes. This study examines lipid-lowering therapies like statins, ezetimibe, and PCSK9 inhibitors for secondary stroke prevention and dyslipidemia management.
Share
Learnings from Implementation Strategies to Improve Lipid Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39775142/
Implementation studies are heterogenous in their strategies and design. At the clinician level, multidisciplinary team-based care (including multidisciplinary lipid clinics), pharmacist- or nurse-led interventions, decision-support algorithms or protocols, and educational...
Optimizing lipid management requires multidisciplinary care, patient adherence strategies, EHR utilization, telehealth, and systematic approaches targeting clinicians, patients, and systems, with future research focusing on long-term outcomes, sustainability, and scalability.
Share
The association of atherogenic index of plasma with cardiovascular outcomes in patients with coronary artery disease: A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38566139/
The results of this study demonstrated that increased AIP is an independent prognostic factors in patients with CAD. Further research is warranted to elucidate the potential development of targeted interventions...
Elevated Atherogenic Index of Plasma (AIP) significantly predicts major cardiovascular events, myocardial infarction, cardiovascular death, and revascularization in coronary artery disease, highlighting its prognostic value and potential for targeted interventions.
Share